Annals of Oncology

Article	Citations
425P Real-world treatment patterns and outcomes in patients with advanced gastric cancer in Japan	1236
342eP Multiomic characterization of early and metastatic biliary tract cancer (BTC)	1034
505eP Real-world efficacy of anlotinib in bevacizumab-treated gastrointestinal cancers	833
501P Bayesian selection of lipidome dynamics features for a K-nearest neighbors (KNN) classifier model of tumor response in patients with advanced gastrointestinal (GI) adenocarcinoma undergoing syste	598
114P Radiologist concordance and pathology correlation in non metastatic colon cancer (NMCC) staging	588
307P AI-driven patient screening for clinical trials in pancreatic cancer: Integrating LLMs with tumor board meetings	529
300P Clinical, pathological, and genomic biomarkers associated with early recurrence in resected localized pancreatic ductal adenocarcinoma (L-PDAC)	508
327P Real world evidence of outcomes and treatment patterns for advanced biliary tract cancer in Saudi Arabia	483
16P Early ctDNA decrease predicts survival in MSI metastatic colorectal cancer treated with immunotherapy	476
139eP Real-world practice of MSI/MMR testing and treatment patterns in colorectal cancer: A nationwide survey in China (SUMMER study)	448
251P Clinical outcomes of rectal squamous cell carcinoma in British Columbia, Canada	434
92P Real-world evidence of a tissue-free ctDNA-based minimal residual disease (MRD) testing in colorectal cancer (CRC): Insights from an Indian cohort	431
11P Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer	364
Title Page	362
CN14 Cancer prevention awareness among Croatian AYA population	352
147P Chemo-immunotherapy with or without consolidative radiotherapy in extensive-stage small cell lung cancer: An initial report of clinical outcome and safety	347
105P CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approaches	342
51P Novel platform combines pathology and transcriptomics for a multi-scale analysis and visualization of the breast tumor heterogeneity	294
82P Obtaining microvesicles from T-lymphocytes using various methods of induction	292
1290TiP A phase II multicenter, open label, non-randomized study of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab in patients with resectable, early-stage (II to IIIA) non-small cell	284
166P Metabolomic prediction of breast cancer treatment toxicities	267
1310P Loratadine: A potential game-changer in lung cancer treatment with improved survival outcomes	248
332P Early prediction of residual cancer burden to neoadjuvant chemotherapy in breast cancer by longitudinal MRI-based multitask learning: A multicenter cohort study	248
2335P Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma	246
1152P Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhi	243

179P Molecular tumor board directed treatment for patients with advanced stage solid tumors: A case-control study	242
1O CircIGF1R_0001 mediates platinum resistance in ovarian cancer that sensitive to PARP inhibitors via promoting PARP1 binding to DNA damage sites	224
1890P Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)	224
1905P Heterogeneity in tertiary lymphoid structures predicts the distinct prognosis and immune microenvironment of clear cell renal cell carcinoma	214
14P Peripheral immune kinetics in survival prediction of small cell lung cancer patients treated with immune checkpoint blockade therapy	209
2092P Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors	206
1590P Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)	203
1176P Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study	198
1601P Relationship between CT and ultrasonography-based sarcopenia and hematologic toxicity in patients with cancer receiving chemotherapy	196
878P INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype	196
1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma	192
2067P Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data	188
CN69 Experiences of patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A qualitative study	185
809P Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship	175
1589P Systemic treatment strategies and outcomes of patients with peritoneal metastases of gastric origin	175
CN55 The impact of psychosocial support on the overall health of cancer patients in the COVID-19 era	174
1608P Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy	169
1296P Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial	169
515P A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients	168
2173P Exploring the complex needs of older patients receiving targeted therapies and immune checkpoint inhibitors for renal and skin cancers at the Royal Marsden Hospital	167
1232P Analytic analysis of PanSeer7, a targeted bisulfite sequencing assay for blood-based multi-cancer detection for cancer early detection and tissue-of-origin identification	167
578P Tissue-resident microbiota characterization in colorectal cancer metastases	162
577P Systematically assessing the intratissue microbiota in 937 patients with colorectal cancer	160
1398P Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)	159
1921MO Patterns of care, outcome and molecular landscape of PATZ1-rearranged sarcomas identifies two prognostic profiles: A cohort study from the French Sarcoma Group (FSG)	156
MO60-4 Tryptophan is the prognostic factor in patients with unresectable pancreatic cancer	154
2132P Unmet needs, quality of life, and financial toxicity in survivors of lung cancer	148
1997P A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer	146
1939P phase I clinical results of SQ3370, a doxorubicin-based click chemistry therapeutic in advanced solid tumor patients	145
56P SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume	141
285O Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: Results from the international HALO study	136
1991P Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial	136
457P Disparities in receipt of CDK4/6 inhibitors with endocrine therapy as therapy for hormone receptor-positive, HER2-negative metastatic breast cancer in the real-world setting	125
365P Radiotherapy treatment outcomes and treatment compliance of nasopharyngeal cancer patients in Sabah: A retrospective analysis	122
402O A randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary	122
1651P Comparison of surgical outcome and prognostic factors between pancreaticobiliary and intestinal types of periampullary adenocarcinoma following pancreaticoduodenectomy	122
1723P Improving access to molecular tumour boards for complex genomic profiles: A healthcare policy from the Netherlands	120
1677P Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma	120
2272P Minimal DNA-methylation (DNAm) signatures for non-invasive tumor-agnostic estimation of tumor content (TC) and molecular subtype in patients (pts) with metastatic breast cancer (mBC)	120
1122P Neutrophil/lymphocyte ratio and systemic inflammatory index as prognostic biomarkers in metastatic melanoma patients under immune checkpoint inhibitors: Could any of them be used?	119
1593MO Combined early palliative care in patients with non small cell lung cancer: A randomised controlled trial in Chongqing, China	115
22P Clinical significance of DNA damage response mutations in early stage NSCLC	112
49P Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer	110
1681P A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer	110
MO48-4 Efficacy and quality of life in blinatumomab treatment in patients with acute lymphoblastic leukemia: Systematic review	109
121P PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium	106
1702P Real-world evidence contributions to European medicines agency’s safety and efficacy evaluations of oncology targeted therapies between 2018-2022	106
907P Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II	103
2116P Preoperative body mass index, waist circumference, and mortality after major cancer surgery: A nationwide cohort study in South Korea	103
936P Triple oral metronomic chemotherapy (OMCT) versus physician choice chemotherapy after failure of platinum-based therapy in advanced head and neck squamous cell cancer (HNSCC): A phase III randomi	102

971P Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China	102
MO68-4 A chemoproteoinformatics approach demonstrates that aspirin increases sensitivity to MEK inhibition by directly binding to RPS5	101
2276P Regulation of major histocompatibility class-I gene methylation using DNA methyltransferase inhibitor and PD-L1 inhibitor in triple-negative breast cancer	97
1707P Cancer drug prices in the US: Efficacy, innovation, clinical trial evidence, and epidemiology	96
505P Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial	96
953P Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial	96
2311P Population pharmacokinetic-pharmacodynamic modeling to inform optimal dosing strategies for GI-101, a novel fusion protein, targeting IL2βγR and CTLA4	95
995P Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada	95
1673P Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: The champ study	95
2293P Protumoral role of neutrophils and neutrophils extracellular traps (NETS) in non-metastatic gastroesophageal and rectal cancers	95
329P Pulmonary function and lung fibrosis up to 12 years after breast cancer radiotherapy	93
201P A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma	93
622P A prognostic and immune infiltration analysis of CCL26 in pan-cancer	92
2028TiP Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small ce	91
1274P Early dynamics of circulating tumor DNA following curative hypofractionated radiotherapy related to disease control in lung cancer	90
195P Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis	90
404P A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer	89
113P Molecular profiling of biliary tract cancers in patients of African and European ancestries	89
213P Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastati	88
430P Real-world patient characteristics and treatment patterns in HR+/HER2+ metastatic breast cancer patients in 5 European countries	88
243P Targeting autophagy in tumor-associated macrophages effects the phenotype and tumor progression in urothelial carcinoma of bladder	84
414P Trastuzumab deruxtecan for HER2-positive breast cancer brain metastasis: A systematic review and meta-analysis	84
34P Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer	84
331MO Comparing data distribution and prognosis of acute myeloid leukemia according to 5th WHO classification and international consensus	81
375P Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital	81
2285P Lower response to COVID-19 booster dose vaccination on cancer patients comparing to healthy controls	81
268P Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study	80
451P The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia	80
404P Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India	79
336P Prognostic and predictive value of Immunoscore in stage III colorectal cancer in the combined SCOT and IDEA-HORG studies	79
398TiP MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure	79
431P Alveolar soft part sarcomas: A tertiary care Indian centre experience	79
P-332 Characteristic and clinical outcome of localized gastric cancer; real-world data	77
350P Primary prevention of chemotherapy-induced neutropenia in patients with advanced lung cancer in real-world research	77
P-85 Treatment propensity and the feasibility of cisplatin plus gemcitabine in elderly patients aged ≥ 75 years with biliary tract cancer	77
285P Reticulocyte hemoglobin equivalent as an early predictor of iron deficiency anemia in cancer patients	75
JS01-3 Optimizing cancer genome medicine in clinical practice in Japan	74
MO36-5 Non-familial prospective risk factors in predicting cancer of unknown primary: A systematic review and meta-analysis	73
P-202 Topical diclofenac in prevention of capecitabine-associated HFS in patients with GI cancers: An exploratory subgroup analysis of the D-ToRCH study	71
LBA65 SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, op	70
MO6-5 Tumor microenvironment and clinical efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma	70
1046P Homologous recombination deficiency (HRD) and genomic associations in non-small cell lung cancer (NSCLC) using a novel HRD signature (HRDsig)	69
1704P Multimodal approach to discover novel targets for antibody-drug conjugates by analyzing distinct expression patterns of frequent copy number aberration	69
ME07 New treatment strategy for hepatobiliary cancer	68
1076P Cancer cachexia associated with gut microbiota and clinical outcomes of patients with non-small cell lung cancer amenable to immunotherapy	68
1485O Percutaneous uterine needle biopsy with microscopic and array-CGH analyses in patients with suspicious myometrial tumors on MRI: A prospective study	68
LBA32 Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer (phase II): Safe and effective in both PD-L1 positi	67
1520P Preferences on treatment decision making in sarcoma patients. Prevalence and associated factors: Results from the PROSa study	66
1474P Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study)	66
1295TiP Investigation of calcium electroporation (CaEP) therapy in malignant cutaneous and subcutaneous tumours: A non-randomized phase II clinical trial of a novel palliative therapy	65
1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition i	64
LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation	64
CN28 Impact of serious illness care program to patients with hematopoietic stem cell transplantation on goals of care documentation and acute healthcare utilization	64
52P HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer - Impact of single-heterozygous UGT1	64
1775P Prevalence of PD-L1 high expression in advanced urothelial carcinoma (aUC): Results from the PREVAIL prospective cohort study	63
1310MO Neoadjuvant platinum-based chemotherapy (NAPC) for metastatic penile squamous cell carcinoma (PSCC): An international, multicenter, real-world study	62
450O Initial monotherapy results of a phase I first-in-human study of ULK1/2 inhibitor DCC-3116 alone and in combination with MAPK pathway inhibition	62
342P A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients	62
1164P Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315)	62
140P Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience	61
461P Spectrum of immune related adverse events (irAE) on treatment with checkpoint inhibitors and its association with survival: A real-world experience from India	61
85P Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): A prospective, multicenter, observational study (ELIXI	61
1779TiP Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001)	61
373P Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2	61
1186TiP EPONA, efficacy of osimertinib with platinum and pemetrexed in EGFR mutant non-small cell lung cancer patients bearing CNS metastasis, and have systemic progression but stable intracranial dis	60
720P Integrative genomic analysis of matched primary and recurrent tumors reveals molecular characteristics of hepatocellular carcinoma with short-term recurrence	60
37P Development of splice switching antisense oligonucleotides targeting midkine	60
70P Genetic alterations and immune cell infiltration with potential impact on PD-(L)1 targeted treatment in various cancer entities: Biobank research project of the INFINITY registry	60
121P Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data	60
202TiP A single-arm, open, multicenter and exploratory clinical study of fluzopari combined with apatinib in pts with platinum-sensitive relapsed ovarian cancer first-line treated with a PARP inhibito	59
P-225 Appraising the potential causal relationships between gut microbiota and colorectal cancer: A two-sample Mendelian randomization analysis	59
39P Clinical relevance of alterations in cancer (CRAC): A DB for selecting biomarkers for molecularly matched therapy in cancer patients	59
238P Budget impact analysis for the health care package by using MammaPrint in Belgium	58
553P Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: Descriptive analysis of the	58
1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metasta	58
P-160 Primary gastrointestinal lymphoma in Latin American patients. A 10-year follow-up	58
O7-4 Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to 1st-line treatment with anti-EGFR antibody: JACCRO CC-16	58
Notice and Disclaimer	57
50P Clinical characteristics, treatment patterns and outcomes of EGFR exon 20 insertion and other EGFR mutations in Korean aNSCLC patients	57
P-111 Increased risk of pancreatic cancer among 141,387 diabetic patients treated with DPP-4 inhibitors analyzed with common data model	56

MO45-3 The efficacy of osimertinib in patients with EGFR-positive non-small cell lung cancer with malignant pleural effusion	56
212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?	56
201P Metastatic and survival characteristics of de novo versus relapsed breast cancer in females aged>35-years-old: A nationwide multicenter study based on hospital population	56
P-177 Sex differences in chemotherapy-induced toxicities in gastric cancer patients	55
P-184 Prognostic value of mTOR expression and mismatch repair gene profile in advanced gastric and gastro-oesophageal cancer	55
MO38-2 Safety and pharmacokinetics (PK) of tusamitamab ravtansine (tusa) in Japanese patients (pts) with advanced solid tumors	54
12P Any size of lymph node metastasis should be considered N1 in patients with cervical cancer	54
P-200 Mutational testing on liquid biopsies for treatment decisions in metastatic colorectal cancer – comparison of ddPCR and MassARRAY methods	53
1640TiP PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced b3-thymoma (B3-T) and thymic carcinoma (TC)	53
224P Adherence to adjuvant hormonal therapy in patients with localized breast cancer	52
44P Breast cancer subtypes in Georgia: Higher frequency of triple-negative breast cancer compared to resource-rich areas	52
SO-10 The prognostic role of microarchitecture in tumour-positive lymph nodes in oesophageal cancer patients: Results from the UK MRC OE02 trial	52
P73-4 Experience with nivolumab in advanced metastatic gastric cancer	52
P-285 Q-TWiST analysis for pembrolizumab plus chemotherapy versus chemotherapy as first-line treatment for patients with advanced esophageal cancer in the KEYNOTE-590 study	51
P-173 Understanding the treatment algorithm of patients with advanced G2 gastroenteropancreatic neuroendocrine neoplasms: A single-institution retrospective analysis	51
1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized tria	50
90P Infrared molecular fingerprinting: A new in vitro diagnostic platform technology for cancer detection in blood-based liquid biopsies	50
P-291 PIK3CA mutations in Tunisian patients with metastatic colorectal cancer: Patient stratification for targeted therapies	49
554P Does the type of hysterectomy affect the survival of patients with clinical IA endometrial cancer: A multicenter and retrospective study	49
1753P Cost-effectiveness (CE) of nivolumab (NIVO) as adjuvant treatment of muscle invasive urothelial carcinoma at high risk of recurrence (MIUC-HR) in France	49
SY12-3 Precision medicine for esophageal cancer	48
P-42 How to improve outcome in high-risk stage III colon cancer with dMMR gene	48
MO1-6 Steroid-resistant and refractory irAEs requiring additional immunosuppressants to steroids in advanced NSCLC patients	48
SY01-1 Novel therapies and Immunotherapy for small cell lung cancer: Finally, some progress	48
P-233 Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: A single-center study, updated with new data	48
P-379 ARID1A as a prognostic biomarker in gastroesophageal cancer: A genomic database analysis	48
P-362 Retrospective analysis of metastatic colorectal cancer based on clinical cancer registry data. Tumor biology, treatment, and outcome	48
LBA33 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in	48
P-404 Survival outcomes and prognostic factors in high risk locally advanced rectal cancers (LARC) undergoing concurrent capecitabine and long course radiation (Cape – RT) – results of a large cohort	48
MO20-3 Outcome of parameningeal head and neck rhabdomyosarcoma in adults: Kyushu Medical Oncology Group Study	47
P-32 Risk factors for early recurrence after radical gastrectomy followed by adjuvant chemotherapy for stage II or III gastric cancer: A multicenter, retrospective study	47
1093P Preliminary biomarker analysis in the phase III PIVOTAL study: Evidence for the mechanism of action of daromun in melanoma	46
1863P Circulating biomarkers for risk stratification of cancer patients with chemotherapy associated febrile neutropenia	46
1182P Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform	46
761P Anti-angiogenic therapy in first-line treatment of low-grade serous ovarian cancer: Exploratory meta-analysis of the prospective AGO-OVAR 11/12/16 studies	46
1632P Impact of androgen pathway inhibitors on cognitive function in elderly patients with metastatic prostate cancer: Results from the COG-PRO trial	45
235MO Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE	45
907P Biomarker analysis of the phase III KEYNOTE-040 study of pembrolizumab (pembro) versus methotrexate, docetaxel, or cetuximab (SOC) for recurrent/metastatic (R/M) head and neck squamous cell carci	45
978P Efficacy and safety analysis of transarterial chemoembolization combined donafenib with or without immune checkpoint inhibitors in for unresectable hepatocellular carcinoma (HCC): A prospective,	45
574P First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 + bevacizumab (beva) in patients (pts) with advanced colorectal cancer (CRC): A phase I study	45
1748P A prospective, phase II study of tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult oft tissue sarcoma (TEASTS)	45
211P GynePDX: A new platform of preclinical models for endometrial and ovarian cancers	45
256P Protein signature of tertiary lymphoid structure predicts efficacy of neoadjuvant chemotherapy in triple-negative breast cancer	45
557P Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals	44
1638P Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age	44
138P Toward predicting immune checkpoint blockade response in oesophageal squamous cell carcinoma: Integrating tumour and blood characteristics	44
727P Real-world efficacy and safety of cadonilimab in recurrent or metastatic cervical cancer: A multicenter retrospective analysis in China	44
1917P Updated survival and vaccine response from the NIPU trial: A randomised, phase II study evaluating nivolumab and ipilimumab with or without UV1 vaccination in patients with pleural mesothelioma	44
1011P Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with adva	43
MO42-5 A phase 2 study of intrapatient dose escalation of bi-weekly FTD/TPI plus BEV for colorectal cancer (E-BiTS study)	43
1747P Changes in global health status (GHS) in patients with advanced soft tissue sarcoma (STS) treated with first line palliative chemotherapy: Primary outcomes from the HOLISTIC study	43
229TiP A phase II trial of a neural network-based treatment decision support tool in patients (pts) with refractory solid organ malignancies	43
MO29-5 Correlation of COVID-19 pandemic and medical seeking behaviour in breast cancer patients at Siloam Hospitals Lippo Village	42
MO43-6 UPRISE study: anxiety in patients with urothelial cancer in postoperative period -relation to patient demographics-	42
SY19-5 Utility of circulating tumor DNA-based MRD monitoring following allogeneic transplantation in adult acute lymphoblastic leukemia	42
MO5-1 Efficacy and safety of olaparib as a potential treatment for patients with pancreatic cancer: a systematic review	41
MO47-4 Neutrophil-lymphocyte ratio predicts prognosis in bone metastasis: meta-analysis of retrospective studies	41
P28-3 Clinical application of portable fNIRS to measure cognitive impairment after chemotherapy in a colorectal cancer patient	41
MO32-5 Impact of patient travel costs on disparities in precision oncology clinical trials	41
MO23-5 A retrospective study of the management of distal lower extremity deep vein thrombosis in patients with cancer	41
P11-9 Association of Charlson Comorbidity Index and safety of endoscopic resection gastric cancer patients: systematic review	40
SY24-KL1 Perioperative chemotherapy for gastric and gastroesophageal junction cancer, European perspective	40
P38-2 Efficacy and safety of lazertinib in the treatment of EGFR-mutated non-small cell lung cancer: a systematic review	40
283P Postoperative adjuvant tislelizumab plus lenvatinib and capecitabine for biliary tract cancer: Interim results of a prospective, single-arm, phase II study	39
418P Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer	39
618P Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer	39
787P First-in-human, phase I study of CBP-1008, a first-in-class bi-specific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors	38
77P Chronologic improvement in survival of first-line oxaliplatin based chemotherapy + targeted therapy for metastatic colorectal cancer (mCRC): Analysis of the ARCAD database	38
202P The impact of statins and proton-pump inhibitors on immune checkpoint inhibition in patients with hepatocellular carcinoma	38
195P Risk factors in patients with hepatocellular carcinoma: A German claims data analysis	38
285P Gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer: A multicenter, single-arm, phase I/II trial	38
225P Nuclear exporter protein exportin 1 (XPO1) as a novel therapeutic target in pancreatic neuroendocrine tumors	37
476P How to predict microsatellite instability (MSI) status in locally advanced gastric cancer? A preoperative CT-based proposal	37
215P Peptide receptor radionuclide therapy versus capecitabine/temozolomide for the treatment of metastatic pancreatic neuroendocrine tumors	37
178P Efficacy and safety of laparoscopic liver resection versus radiofrequency ablation in patients with early and small hepatocellular carcinoma: An updated meta-analysis and meta-regression of obser	37
19P Adjuvant chemotherapy in colon cancer: 6 months better than 3?	37
459P Layer analysis based on RNA-seq data of TCGA reveals gastric cancer's molecular complexity	36
133P The role of determining the diagnostic value of circulating tumor DNA (ctDNA) and natural blood killers (NK) in the diagnosis of precancerous diseases of the colon and colorectal cancer (CRC)	36
45P Neoadjuvant immunotherapy with prolgolimab in locally advanced MSI/dMMR colorectal cancer: Safety and efficacy analysis	36
468P Association of prior and concurrent malignancies with overall survival in a large European single-center gastroesophageal cancer cohort	36
Identifying genetic loci associated with an increased risk for early-onset colorectal cancer	36
13P Genomic signatures of recurrence after resection of node-negative colorectal cancer	35
CN100 Scalp cooling in breast cancer: What are women's experiences? A description and qualitative study	35
386P Exploratory biomarker analysis based on the PREDICT trial (AIO-PAK-0216) for response prediction to second-line nal-IRI/5-FU/FA chemotherapy (CTX) in metastatic PDAC patients (mPDAC Pts)	35
546P An artificial intelligence system integrating deep learning-proteomics, pathomics and clinicopathological features to determine risk of T1 colorectal cancer metastasis to lymph node	35
Table of Contents	35
1913P Five year results of transbronchial microwave ablation of lung malignancies with electromagnetic navigation guidance	35
897P Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma	34
28P Targeting YAP1 as a biomarker of resistance and therapeutic strategy in melanoma immunotherapy	34
1739P Linnovate: A phase I/II study of safety/efficacy using lurbinectedin combined with ipilimumab and nivolumab for advanced soft tissue sarcoma (NCT05876715) - Interim analysis of phase I part	34
1906P ESMO-ESTRO consensus recommendations regarding the safety of combining radiotherapy with targeted agents or immunotherapy	34
1069TiP A phase I/IIa dose escalation and expansion study of 23ME-01473, an anti-ULBP6/2/5 antibody, for patients with advanced solid malignancies	34
913P Characterisation of genomic biomarkers of response to cetuximab versus cisplatin in concomitance with radiotherapy in locally advanced squamous head and neck cancer	33
1990P MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study	33
1163P Prognostic value of systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)	33